Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

SOT106 Lands Dual FDA Designations for Osteosarcoma and Soft Tissue Sarcoma

23 September 2026 · By · Wire by Fusion42

Published

23 September 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 23 September 2026 · Fusion42 review

SOT106 received orphan drug and fast track designations from the FDA for treating osteosarcoma and soft tissue sarcoma, advancing its status before clinical trials begin. The drug targets LRRC15 and showed promising preclinical antitumor activity with a first-in-human trial planned for late 2026.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 23 Sep 2026 and 24 Sep 2026.

◆ ◆ The Wire takeaway

You can access expedited regulatory pathways for sarcoma treatments targeting rare markers like LRRC15 now; start integrating this into your development and market-entry strategies.

◆ Coverage

2 sources · first reported 23 Sep 2026 · latest 24 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfdadesignationantibody-drug-conjugatesarcomarare-diseasedrug-development